Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells

por Mack, Elisabeth K. M., Hartmann, Sören, Ross, Petra, Wollmer, Ellen, Mann, Christoph, Neubauer, Andreas, Brendel, Cornelia, Hoffmann, Jörg
Publicado 2022

Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM

por Kriegsmann, Katharina, Manta, Calin, Schwab, Ricarda, Mai, Elias K., Raab, Marc S., Salwender, Hans J., Fenk, Roland, Besemer, Britta, Dürig, Jan, Schroers, Roland, von Metzler, Ivana, Hänel, Mathias, Mann, Christoph, Asemissen, Anne M., Heilmeier, Bernhard, Bertsch, Uta, Huhn, Stefanie, Müller-Tidow, Carsten, Goldschmidt, Hartmut, Hundemer, Michael
Publicado 2022

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

por Leypoldt, Lisa B., Besemer, Britta, Asemissen, Anne Marie, Hänel, Mathias, Blau, Igor Wolfgang, Görner, Martin, Ko, Yon-Dschun, Reinhardt, Hans Christian, Staib, Peter, Mann, Christoph, Lutz, Raphael, Munder, Markus, Graeven, Ullrich, Peceny, Rudolf, Salwender, Hans, Jauch, Anna, Zago, Manola, Benner, Axel, Tichy, Diana, Bokemeyer, Carsten, Goldschmidt, Hartmut, Weisel, Katja C.
Publicado 2021